Frontier Biotechnologies Inc.
14
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers
Role: lead
A Study of FB2001 for Inhalation in Healthy Chinese Adults
Role: lead
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
Role: lead
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
Role: lead
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
Role: lead
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
Role: lead
A Bridging Study of FB2001 in Healthy Subjects
Role: lead
Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts
Role: collaborator
Test Albuvirtide in Experienced Patients
Role: lead
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
Role: lead
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Role: lead
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
Role: lead
Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects
Role: lead
A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain
Role: lead
All 14 trials loaded